Office Action Predictor
Last updated: April 15, 2026
Application No. 18/306,009

NOVEL CRISPR-ASSOCIATED SYSTEMS AND COMPONENTS

Final Rejection §DP
Filed
Apr 24, 2023
Examiner
LOGSDON, CHARLES
Art Unit
1662
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Arbor Biotechnologies, INC.
OA Round
2 (Final)
72%
Grant Probability
Favorable
3-4
OA Rounds
2y 10m
To Grant
84%
With Interview

Examiner Intelligence

Grants 72% — above average
72%
Career Allow Rate
383 granted / 531 resolved
+12.1% vs TC avg
Moderate +12% lift
Without
With
+11.9%
Interview Lift
resolved cases with interview
Typical timeline
2y 10m
Avg Prosecution
21 currently pending
Career history
552
Total Applications
across all art units

Statute-Specific Performance

§101
7.9%
-32.1% vs TC avg
§103
28.3%
-11.7% vs TC avg
§102
14.4%
-25.6% vs TC avg
§112
38.6%
-1.4% vs TC avg
Black line = Tech Center average estimate • Based on career data from 531 resolved cases

Office Action

§DP
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Status of the Claims Claims 56-57, 59, 61, 63-75 are pending. Claims 56-57, 59, 61, 63-75 are examined herein. The objection to the Specification is withdrawn in view of Applicant’s amendments of the Specification. The rejection to Claims 56-57, 59, 61, 63-75 under 35 USCS 112(a) as failing to comply with the enablement and written description requirements is withdrawn in view of Applicant’s amendments of the claims. The rejections to Claims 65 and 72-73 under 35 U.S.C. 112(b) are withdrawn in view of Applicant’s amendments of the claims. The rejection to Claims 58, 60 and 62 under 35 U.S.C. 101 for statutory double patenting is withdrawn in view of Applicant’s cancelation of the claims. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claims 56-57, 59, 61, 63-75 remain rejected on the ground of nonstatutory double patenting as being unpatentable over claims 56-76 of U.S. Patent No. 11/667904. Although the claims at issue are not identical, they are not patentably distinct from each other because the instant claims, being directed to a genus encompassing sequences having 97% identity to the recited SEQ IDs in Claim 56, represent a genus top the species claimed in claims 56-76 of the reference application. Because the claims are otherwise structured the same and recite the same limitations, the instant claims are prima facie obvious in view of the claims of the reference application. Response to Remarks Applicant did not make any remarks regarding the non-statutory double patenting rejection. Conclusion No claims are allowed. THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. The claims are deemed to be free of the prior art. The closest prior art is Chylinski, et al. "Classification and evolution of type II CRISPR-Cas systems." Nucleic acids research 42.10 (2014): 6091-6105. which teaches CRISPR type II systems, but does not disclose, teach or otherwise render obvious Cas associated proteins having at least 95% identity to any of SEQ ID NO:316-318. Any inquiry concerning this communication or earlier communications from the examiner should be directed to CHARLES A LOGSDON whose telephone number is (571)270-0282. The examiner can normally be reached M-F 8:30 - 5:00 pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Bratislav Stankovic can be reached at (571) 270-0305. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /CHARLES LOGSDON/Primary Examiner, Art Unit 1662
Read full office action

Prosecution Timeline

Apr 24, 2023
Application Filed
Jul 03, 2025
Non-Final Rejection — §DP
Oct 08, 2025
Response Filed
Feb 05, 2026
Final Rejection — §DP
Apr 08, 2026
Response after Non-Final Action

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12593812
HYBRID TOMATO VARIETIES 'E15C42784', 'E15C42790' AND 'E15C42808'
2y 5m to grant Granted Apr 07, 2026
Patent 12593798
SOYBEAN CULTIVAR 25091511
2y 5m to grant Granted Apr 07, 2026
Patent 12588619
PLANTS AND SEEDS OF HYBRID CORN VARIETY CH010554
2y 5m to grant Granted Mar 31, 2026
Patent 12588632
SOYBEAN CULTIVAR 28260109
2y 5m to grant Granted Mar 31, 2026
Patent 12582083
HYBRID TOMATO VARIETY 72-CH0359 RZ
2y 5m to grant Granted Mar 24, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

3-4
Expected OA Rounds
72%
Grant Probability
84%
With Interview (+11.9%)
2y 10m
Median Time to Grant
Moderate
PTA Risk
Based on 531 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in for Full Analysis

Enter your email to receive a magic link. No password needed.

Free tier: 3 strategy analyses per month